Patents by Inventor Jan van de Winkel

Jan van de Winkel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RECOMBINANT FUCOSE MODIFIED MONOVALENT HALF-ANTIBODIES OBTAINED BY MOLECULAR ENGINEERING
    Publication number: 20100255012
    Abstract: Glycosylated monovalent antibodies binding to selected antigens with a low or lacking fucose content, which are capable of inducing antibody dependent cellular cytotoxicity (ADCC) on cells expressing the selected antigens in the presence of effector cells, methods for producing the monovalent antibodies, pharmaceutical compositions comprising such monovalent antibodies and use thereof for different diagnostic and therapeutic applications.
    Type: Application
    Filed: May 30, 2008
    Publication date: October 7, 2010
    Applicant: GENMAB A/S
    Inventors: Janine Schuurman, Tom Vink, Jan Van De Winkel, Aran Frank Labrijn, Paul Parren, Willem Karel Bleeker, Frank Beurskens, Patrick Van Berkel
  • Antibodies against IL-13 receptor alpha1 and uses thereof
    Patent number: 7807158
    Abstract: The instant specification discloses an antibody binding to IL-13R?1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of this antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9, and this antibody is useful in the treatment of asthma and allergic diseases.
    Type: Grant
    Filed: January 3, 2006
    Date of Patent: October 5, 2010
    Assignee: Roche Palo Alto LLC
    Inventors: Josef Endl, Maria Elena Fuentes, Yvo Graus, Adelbert Grossmann, Sebastian Neumann, Paul Parren, Frank Rebers, Joerg Thomas Regula, Ralf Schumacher, Stefan Seeber, Jan Olaf Stracke, Kay-Gunnar Stubenrauch, Jan Van De Winkel, Martine Van Vugt, Sandra Vereecken-Verploegen
  • METHODS OF INHIBITING THE BINDING OF P-SELECTIN TO PSGL-1
    Publication number: 20100209423
    Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
    Type: Application
    Filed: April 27, 2010
    Publication date: August 19, 2010
    Inventors: YVO GRAUS, JACQUES HIMBER, MIRANDA JANSEN-MOLENAAR, DOROTHEE KLING, ERHARD KOPETZKI, PAUL PARREN, FRANK REBERS, BEAT STEINER, ANNE STERN, PAMELA STREIN, KAY-GUNNAR STUBENRAUCH, JAN VAN DE WINKEL, MARTINE VAN VUGT
  • Nucleic acid molecules encoding anti-P-selectin antibodies
    Patent number: 7754867
    Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: July 13, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Strein, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt
  • Anti-OX40L antibodies
    Publication number: 20100166740
    Abstract: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.
    Type: Application
    Filed: December 5, 2008
    Publication date: July 1, 2010
    Inventors: Joseph Endl, Elsie M. Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van de Winkel, Martine Van Vugt
  • BISPECIFIC ANTIBODIES AND METHODS FOR PRODUCTION THEREOF
    Publication number: 20100105874
    Abstract: The invention relates to an ex vivo method for the generation of a bispecific antibody, comprising the steps of: a) providing a first antibody having a first binding specificity, wherein said first antibody comprises an IgG4-like CH3 region, b) providing a second antibody having a second binding specificity which differs from said first binding specificity, wherein said second antibody comprises an IgG4-like CH3 region, c) incubating said first and second antibodies together under reducing conditions which allow the cysteines in the core hinge region to undergo disulfidebond isomerization, and d) obtaining a bispecific antibody. The invention furthermore relates to bispecific antibodies obtainable by the method of the invention.
    Type: Application
    Filed: March 28, 2008
    Publication date: April 29, 2010
    Applicant: GENMAB A/S
    Inventors: Janine Schuurman, Tom Vink, Jan Van De Winkel, Aran Frank Labrijn, Rob Aalberse, Marijn Van Der Neut Kolfschote, Paul Parren
  • COMBINATION TREATMENT OF CD38-EXPRESSING TUMORS
    Publication number: 20100092489
    Abstract: The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non- corticosteroid chemotherapeutic agent.
    Type: Application
    Filed: September 26, 2007
    Publication date: April 15, 2010
    Applicant: GENMAB A/S
    Inventors: Jan Van De Winkel, Paul Parren, Yvo Graus, Judith Oprins, Michel De Weers, Martine Van Vugt, Ole Baadsgaard, Steen Lisby
  • ANTI-P-SELECTIN ANTIBODIES
    Publication number: 20090311779
    Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
    Type: Application
    Filed: June 10, 2009
    Publication date: December 17, 2009
    Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Strein, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt
  • ANTIBODIES AGAINST INSULIN-LIKE GROWTH FACTOR I RECEPTOR AND USES THEREOF
    Publication number: 20090275126
    Abstract: Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Such antibodies are implicated in antitumor therapy.
    Type: Application
    Filed: July 17, 2009
    Publication date: November 5, 2009
    Inventors: Yvo Graus, Erhard Kopetzki, Klaus-Peter Kuenkele, Olaf Mundigl, Paul Parren, Frank Rebers, Ralf Schumacher, Jan van de Winkel, Martine Vriesema-van Vugt
  • RECOMBINANT MONOVALENT ANTIBODIES AND METHODS FOR PRODUCTION THEREOF
    Publication number: 20090226421
    Abstract: The present invention provides monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies.
    Type: Application
    Filed: November 28, 2006
    Publication date: September 10, 2009
    Applicant: GENMAB A/S
    Inventors: Paul Parren, Janine Schuurman, Tom Vink, Willem Karel Bleeker, Jan Van De Winkel, Patrick Van Berkel, Frank Beurskens
  • Antibody selection method against IGF-IR
    Patent number: 7579157
    Abstract: Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing the antibodies, and uses for the antibodies are disclosed. Antibodies against IGF-IR are implicated in antitumor therapy.
    Type: Grant
    Filed: July 8, 2004
    Date of Patent: August 25, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Yvo Graus, Erhard Kopetzki, Klaus-Peter Kuenkele, Olaf Mundigl, Paul Parren, Frank Rebers, Ralf Schumacher, Jan van de Winkel, Martine Vriesema-van Vugt
  • Antibodies against insulin-like growth factor I receptor and uses thereof
    Patent number: 7572897
    Abstract: Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Antibodies against IGF-IR are implicated in antitumor therapy.
    Type: Grant
    Filed: October 9, 2007
    Date of Patent: August 11, 2009
    Assignee: Hoffman-La Roche Inc.
    Inventors: Yvo Graus, Erhard Kopetzki, Klaus-Peter Kuenkele, Olaf Mundigl, Paul Parren, Frank Rebers, Ralf Schumacher, Jan van de Winkel, Martine Vriesema-van Vugt
  • Anti-P-selectin antibodies
    Patent number: 7563441
    Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: July 21, 2009
    Assignee: Hoffman-La Roche Inc.
    Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Strein, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt
  • Antibodies against cd38 for treatment of multiple myeloma
    Publication number: 20090148449
    Abstract: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: March 23, 2006
    Publication date: June 11, 2009
    Applicant: Genmab A/S
    Inventors: Michel De Weers, Yvo Graus, Judith Oprins, Paul Parren, Jan Van De Winkel, Martine Van Vugt
  • Non-Human mammalian Arthritis Model Featuring Human Antibodies Against Citrul-Linated Proteins
    Publication number: 20090117584
    Abstract: Use of a non-human mammalian disease model, wherein the non-human mammal has been implanted with human synovial tissue or other human inflamed tissue containing anti-CCP (cyclic citrullinated peptide) antibody producing cells for (i) analyzing cellular processes in a disease associated with anti-CCP antibodies in such human synovial tissue or other human inflamed tissue, (ii) studying the role of anti-CCP antibodies in the induction and progression of a disease associated with anti-CCP antibodies, (iii) testing the efficacy of a therapeutic agent for the prevention or treatment of a disease associated with anti-CCP antibodies, and (iv) identifying a therapeutic agent useful for the prevention or treatment of a disease associated with anti-CCP antibodies. In one embodiment the non-human mammalian disease model is a mouse, such as a SCID mouse, and the disease associated with anti-CCP antibodies is arthritis, such as RA (rheumatoid arthritis).
    Type: Application
    Filed: June 29, 2006
    Publication date: May 7, 2009
    Applicant: GENMAB A/S
    Inventors: Rene Toes, Thomas Huizinga, Miranda Molenaar, Paul Parren, Jan Van De Winkel
  • Antibodies against CD38 for treatment of multiple myeloma
    Publication number: 20090076249
    Abstract: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: September 19, 2007
    Publication date: March 19, 2009
    Inventors: Michel De Weers, Yvo Graus, Judith Oprins, Paul Parren, Jan Van De Winkel, Martine Van Vugt
  • Anti-OX40L antibodies
    Patent number: 7501496
    Abstract: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: March 10, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Joseph Endl, Elsie M. Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van De Winkel, Martine Van Vugt
  • Human Monoclonal Antibodies Against Cd20
    Publication number: 20080260641
    Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: April 20, 2005
    Publication date: October 23, 2008
    Inventors: Jessica Teeling, Martin Glennie, Paul Parren, Arnout F. Gerritsen, Sigrid Ruuls, Yvo Graus, Jan van de Winkel
  • ANTIBODIES AGAINST INSULIN-LIKE GROWTH FACTOR I RECEPTOR AND USES THEREOF
    Publication number: 20080132686
    Abstract: Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Such antibodies are implicated in antitumor therapy.
    Type: Application
    Filed: October 9, 2007
    Publication date: June 5, 2008
    Inventors: Yvo Graus, Erhard Kopetzki, Klaus-Peter Kuenkele, Olaf Mundigl, Paul Parren, Frank Rebers, Ralf Schumacher, Jan van de Winkel, Martine Vriesema-van Vugt
  • Antibodies against insulin-like growth factor 1 receptor and uses thereof
    Patent number: 7378503
    Abstract: Antibodies which bind to IGF-IR and inhibit the binding of IGF-I and IGF-II to IGF-IR are characterized. These antibodies are implicated in anti-tumor therapy.
    Type: Grant
    Filed: April 1, 2004
    Date of Patent: May 27, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Yvo Graus, Erhard Kopetzki, Klaus-Peter Kuenkele, Olaf Mundigl, Paul Parren, Frank Rebers, Ralf Schumacher, Jan van de Winkel, Martine Vriesema-van Vugt